Perspective from Jason Bacharach, MD
Source: Press Release
Disclosures: Baum is employed by Harrow Health.
December 20, 2021
1 min read
Save

Harrow Health acquires US rights to four eye drops

Perspective from Jason Bacharach, MD
Source: Press Release
Disclosures: Baum is employed by Harrow Health.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Harrow Health acquired the United States commercialization rights to four ophthalmic drops from Novartis, according to a press release.

The acquisition includes the 1% and 0.5% formulations of Iopidine (apraclonidine hydrochloride), Maxitrol 0.1% (neomycin and polymyxin B sulfate and dexamethasone) and Moxeza 0.5% (moxifloxacin hydrochloride).

The company plans to sell, market and distribute the products through subsidiary, ImprimisRx. Novartis will retain commercial rights outside of the U.S.

“These acquisitions, along with previously announced transactions for AMP-100, MAQ-100, and the expansion of our relationship to sell and market Dexycu, are consistent with our strategic mission to leverage the ImprimisRx commercial platform by adding high-value FDAapproved products into our family of ophthalmic pharmaceutical products,” Harrow Health CEO, Mark L. Baum, said in the release. “We are excited about the benefits these newest products provide our more than 10,000 customers, and we expect ImprimisRx’s commercial and distribution platform to be a tremendous advantage in the lifecycle management of these clinically valuable medicines.”